CJ Bioscience, Inc. (KOSDAQ:311690)

CJ Bioscience Statistics

Total Valuation

CJ Bioscience has a market cap or net worth of KRW 117.85 billion. The enterprise value is 64.85 billion.

Market Cap	117.85B
Enterprise Value	64.85B

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

CJ Bioscience has 13.07 million shares outstanding. The number of shares has increased by 29.38% in one year.

Current Share Class	13.07M
Shares Outstanding	13.07M
Shares Change (YoY)	+29.38%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	3.54%
Owned by Institutions (%)	0.11%
Float	4.51M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	34.85
PB Ratio	1.81
P/TBV Ratio	2.21
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.11
EV / Sales	19.17
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.34

Financial Position

The company has a current ratio of 4.47, with a Debt / Equity ratio of 0.13.

Current Ratio	4.47
Quick Ratio	4.42
Debt / Equity	0.13
Debt / EBITDA	n/a
Debt / FCF	-0.30
Interest Coverage	-55.94

Financial Efficiency

Return on equity (ROE) is -50.69% and return on invested capital (ROIC) is -28.81%.

Return on Equity (ROE)	-50.69%
Return on Assets (ROA)	-25.23%
Return on Invested Capital (ROIC)	-28.81%
Return on Capital Employed (ROCE)	-46.66%
Revenue Per Employee	27.72M
Profits Per Employee	-252.02M
Employee Count	122
Asset Turnover	0.04
Inventory Turnover	15.30

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -17.33% in the last 52 weeks. The beta is 0.62, so CJ Bioscience's price volatility has been lower than the market average.

Beta (5Y)	0.62
52-Week Price Change	-17.33%
50-Day Moving Average	9,714.00
200-Day Moving Average	9,982.95
Relative Strength Index (RSI)	39.04
Average Volume (20 Days)	18,698

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CJ Bioscience had revenue of KRW 3.38 billion and -30.75 billion in losses. Loss per share was -2,732.78.

Revenue	3.38B
Gross Profit	360.29M
Operating Income	-31.92B
Pretax Income	-30.75B
Net Income	-30.75B
EBITDA	-27.76B
EBIT	-31.92B
Loss Per Share	-2,732.78

Balance Sheet

The company has 61.29 billion in cash and 8.29 billion in debt, giving a net cash position of 53.00 billion or 4,056.63 per share.

Cash & Cash Equivalents	61.29B
Total Debt	8.29B
Net Cash	53.00B
Net Cash Per Share	4,056.63
Equity (Book Value)	65.19B
Book Value Per Share	4,989.85
Working Capital	48.57B

Cash Flow

In the last 12 months, operating cash flow was -27.29 billion and capital expenditures -380.49 million, giving a free cash flow of -27.67 billion.

Operating Cash Flow	-27.29B
Capital Expenditures	-380.49M
Free Cash Flow	-27.67B
FCF Per Share	-2,117.50

Margins

Gross Margin	10.65%
Operating Margin	-943.91%
Pretax Margin	-909.10%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CJ Bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-29.38%
Shareholder Yield	-29.38%
Earnings Yield	-26.09%
FCF Yield	-23.48%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CJ Bioscience has an Altman Z-Score of 1.41 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.41
Piotroski F-Score	2